---
title: "Obefazimod (ABX464) in Ulcerative colitis: Economic burden and healthcare resource utilization"
description: "Formulary evidence on Obefazimod (ABX464) in Ulcerative colitis: Economic burden and healthcare resource utilization. Topics: National economic burden of ulcerative colitis in the United States; National economic burden of inflammatory bowel disease in the United States; Lifetime health care costs of ulcerative colitis by age at diagnosis in 85,755 patients; Annual direct costs in 52,782 commercially insured and Medicare Advantage patients with inflammatory bowel disease, 29,062 with ulcerative colitis; 9 further topics. 13 evidence topics quoted from 12 sources."
canonical: "https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/product-information-and-disease-description/economic-burden-and-healthcare-resource-utilization"
published: "2026-11-18T10:42:55-05:00"
modified: "2026-11-18T10:42:55-05:00"
---

# Obefazimod (ABX464) in Ulcerative colitis: Economic burden and healthcare resource utilization

<a id="heading-2.2.1.8.2"></a>

## 2.2.1.8.2 Economic Burden and Healthcare Resource Utilization

<a id="topic-2.2.1.8.2-1"></a>

### National economic burden of ulcerative colitis in the United States

> “It is estimated that approximately 900,000 individuals in the United States (US) have UC.4 The economic burden of UC is significant, ranging between an estimated $15-32 billion per year.”

Source: [ICER Targeted Immune Modulators for Ulcerative Colitis final evidence report (2020)](https://icer.org/wp-content/uploads/2020/08/ICER_UC_Final_Evidence_Report_101620.pdf)

<a id="topic-2.2.1.8.2-2"></a>

### National economic burden of inflammatory bowel disease in the United States

> “The economic burden of IBD is significant, with recent estimates of $50 billion per year in the United States.”

Source: [ICER special assessment of Entyvio to inform CMS negotiation (2026)](https://icer.org/wp-content/uploads/2026/03/Entyvio_Final-Evidence-Report_For-Publication_030326.pdf)

<a id="topic-2.2.1.8.2-3"></a>

### Lifetime health care costs of ulcerative colitis by age at diagnosis in 85,755 patients

> “We collected data from 78,620 patients with CD, 85,755 with UC, and propensity score-matched control subjects from the Truven Health MarketScan insurance claims databases (2008‒2015).”
> “Cost variations over a lifetime were estimated in cost-state Markov models by age at diagnosis, adjusted to 2016 U.S. dollars and discounted at 3% per annum.”
> “For UC, the lifetime incremental cost was $369,955 among patients who received their diagnosis at 0‒11 years, and $132,396 for individuals 70 years or older, averaging $230,102 for a diagnosis at any age. Lifetime total cost was $405,496, consisting of outpatient ($163,670), inpatient ($123,190), pharmacy ($105,142), and ER ($13,493) costs.”
> “Therefore, the prevalent populations of patients with CD or UC in the United States in 2016 are expected to incur lifetime total costs of $498 billion and $377 billion, respectively.”

Source: [Lichtenstein et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/31326606/)

<a id="topic-2.2.1.8.2-4"></a>

### Annual direct costs in 52,782 commercially insured and Medicare Advantage patients with inflammatory bowel disease, 29,062 with ulcerative colitis

> “There were 52,782 IBD patients (29,062 UC; 23,720 CD) included in the analysis (54.1% females). On a per-annual basis, patients with IBD incurred a greater than 3-fold higher direct cost of care compared with non-IBD controls ($22,987 vs $6956 per-member per-year paid claims)”
> “The burden of costs was most notable in the first year after initial IBD diagnosis (mean = $26,555). The study identified several key drivers of cost for IBD patients: treatment with specific therapeutics (biologics, opioids, or steroids); ED use; and health care services associated with relapsing disease, anemia, or mental health comorbidity.”
> “As shown, although mean all-cause costs of IBD were stable from year to year before 2012, costs have been rising for CD and UC, particularly after 2013.”

Source: [Park et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7534391/)

<a id="topic-2.2.1.8.2-5"></a>

### Costs of treatment failure with first-line advanced therapy in 5302 adults with moderate-to-severe ulcerative colitis

> “Analysis of treatment failure patterns included data from 6745 patients; HCRU and cost analyses included data from 5302 patients (treatment failure cohort, n = 4295; persistent cohort, n = 1007). In the overall population, 75% experienced treatment failure within the first 12 months (median: 5.1 months).”
> “The treatment failure cohort had significantly (P < .001) higher mean costs than the persistent cohort (all-cause, $74 995 vs $56 169; UC-related, $57 096 vs $47 347) mainly attributed to inpatient admissions and outpatient visits. Dose escalation/interval shortening accounted for the highest total costs ($101 668) across treatment failure events.”

Source: [Lee et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11094759/)

<a id="topic-2.2.1.8.2-6"></a>

### Hospitalization and costs in the 12 months after initiating immunosuppressant or biologic therapy in 3562 patients

> “In total, 3562 patients were included in the analysis. Most patients (83.0%) used steroids in the 12 months before initiating advanced therapy. Overall, 47.8% remained steroid-free after 12 months (excluding tapering).”
> “Overall, 12.2% of patients had a UC-related hospitalization within 12 months of initiation, with a mean (SD) total length of stay of 8.2 (8.9) days and no significant differences between biologic therapies. Mean, unadjusted, UC-related costs in the 12 months postinitiation were $42,579 and were similar between therapies.”

Source: [Long et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7216775/)

<a id="topic-2.2.1.8.2-7"></a>

### Health care resource use and costs associated with chronic corticosteroid use

> “Targeted treatment initiators included 1,886 chronic and 1,911 nonchronic corticosteroid users; conventional therapy initiators included 4,980 chronic and 5,199 nonchronic users. Chronic vs nonchronic users had 94% more inpatient days and 16% more outpatient visits among targeted treatment initiators, and 135% more inpatient days and 30% more outpatient visits among conventional therapy initiators (all P < 0.01).”
> “Mean all-cause total costs per patient per year were $73,491 for chronic vs $58,884 for nonchronic users ($14,607 higher; P < 0.01) for targeted treatment initiators, and $39,335 for chronic vs $21,271 for nonchronic users ($18,065 higher; P < 0.01) for conventional therapy initiators.”

Source: [Zhdanava et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10839463/)

<a id="topic-2.2.1.8.2-8"></a>

### Hospitalization and colectomy after diagnosis in 3,893 commercially insured adults with newly diagnosed ulcerative colitis

> “Among 3,893 patients with newly diagnosed UC (age at diagnosis, 41±14y; 52% male; 80% White, 7.2% Black and 8.2% Hispanic patients) followed over 4.2±3.0y, 5-year risk of IBD-related hospitalization, colectomy and serious infection was 11%, 6%, and 10%, respectively, with lower risk in Hispanic patients (vs. White patients).”
> “Cumulative 5y risk of all-cause and IBD-related hospitalization was 17% (95% CI, 16–19) and 11% (95% CI, 10–12), respectively (Table 2). Risk of all-cause and IBD-related hospitalization remained stable over era of IBD diagnosis (Figure 2D).”

Source: [Ahuja et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13456955/)

<a id="topic-2.2.1.8.2-9"></a>

### Indirect costs of work impairment by disease activity in 282 US patients with ulcerative colitis

> “The analyses included 281 patients with CD and 282 patients with UC.”
> “In UC, absenteeism (0.6%–11.9%), presenteeism (7.1%–37.1%), and overall work impairment (7.5%–41.9%) increased with increasing disease activity (all P < .0001). Annual indirect costs due to total work impairment increased with increasing disease activity (all P < .0001), from $7169/patient/year (remission) to $29 524/patient/year (moderately-to-severely active disease) in CD and $4348/patient/year (remission) to $24 283/patient/year (moderately-to-severely active disease) in UC.”

Source: [Ding et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9802455/)

<a id="topic-2.2.1.8.2-10"></a>

### Hospitalization costs of nonelective colectomy or rectal resection in 10,280 US adults

> “All adults with UC in the 2016-2020 Nationwide Readmissions Database undergoing nonelective colectomy or rectal resection were identified.”
> “An estimated 10,280 patients met study criteria with median index hospitalization costs of $40,300 (IQR, $26,400-$65,000). Increased time to surgery was significantly associated with a +$2500 increment in costs per day. Compared with low-volume hospitals, medium- and high-volume centers demonstrated a -$5900 and -$8200 reduction in costs, respectively.”

Source: [Ng et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38583900/)

<a id="topic-2.2.1.8.2-11"></a>

### Colectomy cost per admission used in the ICER 2020 model

> “A cost of $33,871 per admission for colectomy is assumed, calculated by the weighted average cost of emergent and non-emergent cost per admission from the Healthcare Cost and Utilization Project (HCUP) National Inpatient Sample (NIS) database”

Source: [ICER Targeted Immune Modulators for Ulcerative Colitis final evidence report (2020)](https://icer.org/wp-content/uploads/2020/08/ICER_UC_Final_Evidence_Report_101620.pdf)

<a id="topic-2.2.1.8.2-12"></a>

### Direct medical costs before and after proctocolectomy in a population-based cohort of 60 patients

> “Operations included ileal-pouch anal anastomosis (n=45, mean cost of surgery/recovery period $50,530) or total proctocolectomy with Brooke ileostomy (n=15, mean cost of surgery/recovery period $39,309). In the pouch subgroup, direct medical costs on average were reduced by $9,296 (P<0.001, bootstrapped 95% CI: $324 to $15,628) in the 2-years after recovery.”
> “Mean costs are reported in 2007 constant dollars.”

Source: [Holubar et al. (2009)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2791910/)

<a id="topic-2.2.1.8.2-13"></a>

### Costs, resource use, and quality of life with advanced therapies: systematic review of US and European observational studies

> “47 publications of 40 unique cost/HCRU studies and 13 publications of nine unique HRQoL studies were included. Findings demonstrated that biologics have a positive impact on indirect costs (i.e., productivity, presenteeism, and absenteeism) and HRQoL. High costs of biologics were not always fully offset by reductions in cost and HCRU associated with disease management. For many patients, treatment switching and dose escalations were required, thus increasing drug costs, particularly when switching across treatment classes.”

Source: [Cichewicz et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10130125/)

## Related pages
- [Obefazimod (ABX464): Ulcerative colitis](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Terms and abbreviations](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/terms-and-abbreviations.md)
- [Obefazimod (ABX464): Ulcerative colitis](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/executive-summary.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Product information and disease description](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/product-information-and-disease-description.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Clinical evidence](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/clinical-evidence.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Economic information and modeling report](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/economics) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/economics.md)
- [Obefazimod (ABX464) in Ulcerative colitis: References](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/references) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/references.md)
